English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Third and fourth line chemotherapy agents are not helpful in the setting of extensive stage small cell lung cancer ( SCLC ). We describe the case of a 43‐year‐old  K orean patient with  T4N3M1b  extensive stage  SCLC  who responded remarkably well to treatment and experienced a prolonged progression‐free survival ( PFS ) period following treatment with fourth line ifosfamide and carboplatin after experiencing disease progression with three previous regimens. Additionally, third line cyclophosphamide, doxorubicin (Adriamycin), and vincristine demonstrated long‐term  PFS  periods.

thoracic cancer

Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine ( CAV ) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer